Sign in

    Mara Goldstein

    Managing Director and Senior Biotechnology Research Analyst at Mizuho

    Mara Goldstein is a Managing Director and Senior Biotechnology Research Analyst at Mizuho, specializing in equity research on biotechnology and pharmaceutical companies with a focus on immuno-oncology and innovation-driven healthcare firms. She covers a broad range of biotech names including Incyte, Syndax, Autolus, Corvus, IN8bio, Iovance, and Xencor, and has issued numerous recommendations across the sector, though her most recent performance metrics reflect a success rate of approximately 34% and an average return per recommendation of -5.3%. Goldstein began her career with positions at Alex. Brown & Sons, CIBC World Markets, and Thomson Reuters, then served as Senior Managing Director and Director of Research at Cantor Fitzgerald before joining Mizuho as Managing Director in late 2018. She holds a Bachelor of Science in Economics from Purdue University and brings over 25 years of experience in healthcare equity research.

    Mara Goldstein's questions to FATE THERAPEUTICS (FATE) leadership

    Mara Goldstein's questions to FATE THERAPEUTICS (FATE) leadership • Q3 2023

    Question

    Asked how FT819 compares to the broader field of CARs in autoimmunity, whether it's seen as a 'bridge' to other constructs, and how many U.S. sites will be initiated for the autoimmune study.

    Answer

    The company stated it's too early for the field to determine the optimal therapeutic requirements for cell therapies in autoimmunity and that much will be learned in the coming months. Regarding trial sites, they are partnering with their experienced oncology sites (12-15 are open for the 819 oncology study) to collaborate with autoimmune specialists, facilitating a smoother start.

    Ask Fintool Equity Research AI

    Mara Goldstein's questions to Xencor (XNCR) leadership

    Mara Goldstein's questions to Xencor (XNCR) leadership • Q3 2023

    Question

    Asked about the timing of potential milestones for XmAb306, the positioning of vudalimab in renal cell carcinoma, and the timeline for the CFO search.

    Answer

    The company cannot yet speculate on the timing of XmAb306 milestones. They are not planning to pursue RCC with vudalimab despite positive competitor data for the drug class in that indication. The search for a new CFO has already begun.

    Ask Fintool Equity Research AI

    Mara Goldstein's questions to SNSS leadership

    Mara Goldstein's questions to SNSS leadership • Q3 2016

    Question

    Mara Goldstein of Cantor Fitzgerald questioned if the SNS-062 trial would still use twice-a-day dosing and how the planned daily dose would compare to levels tested in the healthy volunteer study. She also asked about the commercial strategy for Europe, specifically if the company was considering multiple partners to cover different geographies.

    Answer

    Debbie Thomas, SVP of Regulatory Affairs, confirmed a twice-a-day dosing regimen for SNS-062, supported by its half-life, and noted that dose escalation could exceed the total daily dose tested in the single-dose study. On the commercial front, President and CEO Dan Swisher stated they are only looking at European-wide partnerships. CFO Eric Bjerkholt added that the company is actively engaged in pre-commercial efforts, including KOL advocacy and supply chain establishment, to position a partner for success.

    Ask Fintool Equity Research AI